artus therapeutics
- Company typePrivate
- Founded-
- HeadquartersCambridge, United States
- Headcount—
- GTM typeB2B
- OfferingHardware or Manufacturing
artus therapeutics firmographics
Firmographics- Name
- artus therapeutics
- Legal name
- Artus Therapeutics, Inc.
- Website
- https://www.artustx.com
- Company type
- Private
- Operating status
- Operating
- Ownership category
- akta.pro rank
Where artus therapeutics is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
artus therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Marketing channels2 records
artus therapeutics product offering
Product offeringCore offering
Artus Therapeutics is developing first-in-class oral small molecule therapeutics for inflammatory, autoimmune, gastrointestinal, neurological, and metabolic diseases by targeting gut barrier dysfunction. Using its Artx™ platform, the company creates new molecular entities inspired by beneficial naturally occurring host or microbial metabolites that enhance epithelial and endothelial barrier integrity and facilitate mucosal healing without compromising immunity.
Product overview
Artus Therapeutics offers the ArtxTM drug design and development platform, which is used to create new molecular entities (NMEs) inspired by beneficial naturally occurring host or microbial metabolites. The platform supports three developmental lead candidates: Artx-405, Artx-413, and Artx-425. These are oral small molecule therapeutics designed to enhance epithelial and endothelial barrier integrity, facilitating mucosal healing without compromising immunity. The candidates target gastrointestinal, neurological, and metabolic disorders through gut barrier dysfunction mechanisms.
Differentiator
Problem solved
Functional benefit
Brands
- ArtxTM platform: A drug design and development platform developing new molecular entities (NME) inspired by beneficial naturally occurring host or microbial metabolites for oral small molecule therapies.
Products and services
- Artx™ Platform A proprietary drug design and development platform that creates new molecular entities (NMEs) inspired by beneficial naturally occurring host or microbial metabolites. The platform supports development of oral small molecule therapies that enhance barrier integrity of both epithelial and endothelial cells, intended for gastrointestinal, neurological, and metabolic disorders.
- Artx-405 A pre-clinical lead therapeutic candidate designed to enhance epithelial and endothelial barrier integrity, facilitating mucosal healing without compromising immunity. Developed within the Artx™ platform for inflammatory, gastrointestinal, neurological, and metabolic indications.
- Artx-413 A pre-clinical lead therapeutic candidate designed to enhance epithelial and endothelial barrier integrity, facilitating mucosal healing without compromising immunity. Developed within the Artx™ platform for inflammatory, gastrointestinal, neurological, and metabolic indications.
- Artx-425 A pre-clinical lead therapeutic candidate designed to enhance epithelial and endothelial barrier integrity, facilitating mucosal healing without compromising immunity. Developed within the Artx™ platform for inflammatory, gastrointestinal, neurological, and metabolic indications.
Companies that use artus therapeutics
Customer profileSegments2 records
Ideal customer profiles2 records
artus therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
artus therapeutics partnerships and signals
Strategic signalScale indicators1 record
Recent moves3 records
Expansion highlights3 records
artus therapeutics competitors and assessment
Company assessmentEmerging players
- Vedanta Biosciences: Vedanta develops live biotherapeutic products defined from the human microbiome for inflammatory and autoimmune diseases. Comparable as a gut-microbiome-inspired therapeutics company, though focused on live biotherapeutics rather than small molecules.
- Assembly Biosciences: Assembly Biosciences is a clinical-stage small-molecule biotech with programs in virology and microbiome-derived therapeutics. Comparable on being a small-molecule biotech with microbiome-adjacent discovery.
- Synlogic: Synlogic engineers synthetic-biology-based microbial therapeutics for metabolic and inflammatory diseases. Comparable on gut-microbiome-derived therapeutic design, though using engineered organisms rather than small-molecule NMEs.
- Kaleido Biosciences: Kaleido developed microbiome metabolite-based therapies for inflammatory and metabolic diseases. Closely comparable concept of metabolite-inspired drug discovery targeting gut-driven systemic inflammation.
- Finch Therapeutics: Finch develops microbiome-derived therapeutics for inflammatory bowel disease and other GI conditions. Comparable on gut-microbiome approach to inflammatory disease, but using whole microbial consortia rather than small molecules.
- Second Genome: Second Genome identifies microbiome-derived targets and develops small-molecule and biologic drugs for inflammatory and metabolic disease. Closely comparable on combining microbiome biology with small-molecule drug discovery.
- 4D pharma: 4D pharma develops live biotherapeutics for inflammatory, oncologic and respiratory disease using single-strain microbiome bacteria. Adjacent comparison on gut-microbiome-derived therapeutics targeting inflammation.
Direct peers
- Enterome: Enterome develops small-molecule and peptide drugs inspired by microbiome/bacterial metabolites for inflammatory bowel disease and immuno-oncology. Directly comparable to Artus on the metabolite-inspired chemistry approach targeting gut-driven inflammation.
- Axial Therapeutics: Axial Therapeutics develops gut-brain-axis targeted small molecules for neurological and neurodevelopmental disorders. Comparable as a small-molecule biotech targeting CNS conditions via gut-derived mechanisms.
Broad incumbents
- Intercept Pharmaceuticals: Intercept developed obeticholic acid, an oral small-molecule FXR agonist for chronic liver and metabolic disease. Comparable as an established oral small-molecule company pursuing metabolic/inflammatory indications via a single differentiated mechanism.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat2 records
Key risks6 records
Key highlights6 records
Customer concentration
artus therapeutics social profiles
Digital presenceartus therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
artus therapeutics leadership team
Management profileNumber of profiles
Profiles2 records
artus therapeutics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
artus therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about artus therapeutics
What does artus therapeutics do?
Artus Therapeutics is developing first-in-class oral small molecule therapeutics for inflammatory, autoimmune, gastrointestinal, neurological, and metabolic diseases by targeting gut barrier dysfunction. Using its Artx™ platform, the company creates new molecular entities inspired by beneficial naturally occurring host or microbial metabolites that enhance epithelial and endothelial barrier integrity and facilitate mucosal healing without compromising immunity.
Is artus therapeutics a public or private company?
artus therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was artus therapeutics founded?
artus therapeutics was founded in -1.
Where is artus therapeutics based?
artus therapeutics is headquartered in Cambridge, United States, in the North America region.
Who are artus therapeutics's main competitors?
Emerging players on record are Vedanta Biosciences, Assembly Biosciences, Synlogic, Kaleido Biosciences, Finch Therapeutics, Second Genome and 4D pharma. Direct peers are Enterome and Axial Therapeutics. Intercept Pharmaceuticals is listed as a broad incumbent.
Does artus therapeutics have an API?
No public API is recorded for artus therapeutics.